SCHEMBL3347834

SCHEMBL3347834

CCCCCC(=O)COC(C)=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
FAAH O00519 2/20 0.52
KMT2A Q03164 2/20 0.48
MAPT P10636 1/20 0.48
PAM P19021 2/20 0.47
DGKA P23743 1/20 0.47
CES2 O00748 4/20 0.46
CES1 P23141 4/20 0.46
AKR1B1 P15121 1/20 0.44
HAO1 Q9UJM8 1/20 0.44
PPARG P37231 4/20 0.43
PPARD Q03181 4/20 0.43
PPARA Q07869 4/20 0.43
TSHR P16473 3/20 0.43
GPR84 Q9NQS5 3/20 0.43
HDAC11 Q96DB2 3/20 0.43
TDP1 Q9NUW8 2/20 0.43
SLC22A6 Q4U2R8 1/20 0.43
SLC22A8 Q8TCC7 1/20 0.43
TLR2 O60603 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5165888 0.98 FAAH (0.55) ALDH1A1FAAHKMT2AMAPTPAM
SCHEMBL15903150 0.98 FAAH (0.55) ALDH1A1FAAHKMT2AMAPTPAM
SCHEMBL5182290 0.98 FAAH (0.55) ALDH1A1FAAHKMT2AMAPTPAM
SCHEMBL4940224 0.98 FAAH (0.55) ALDH1A1FAAHKMT2AMAPTPAM
SCHEMBL30845971 0.98 FAAH (0.55) ALDH1A1FAAHKMT2AMAPTPAM
SCHEMBL28294939 0.96 FAAH (0.53) ALDH1A1FAAHKMT2AMAPTPAM
SCHEMBL31197399 0.93 ALDH1A1 (0.54) ALDH1A1FAAHKMT2AMAPTPAM
SCHEMBL16146942 0.88 FAAH (0.54) ALDH1A1FAAHKMT2AMAPTPAM
SCHEMBL5167241 0.88 FAAH (0.65) FAAHKMT2AMAPTPPARGPPARD
SCHEMBL5167253 0.88 FAAH (0.65) FAAHKMT2AMAPTPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727750-B2 Biocatalytic asymmetric reduction in preparation of (S)-N-[5-(1,2-dihydroxy-ethyl)-pyrazinyl]-2,2-dimethyl-propionamide HOFFMAN-LA ROCHE INC. (US) 2010-06-01 US disclosed
EP-2145012-A2 MICROBIAL REDUCTION OF AN ACETOXYKETONE F. Hoffmann-Roche AG (CH) 2010-01-20 EP disclosed
WO-2008122511-A2 PROCESS FOR PREPARING 2-AMINO- [5-(1(S), 2-DIHYDROXYETHYL) OR - (KS) -HYDROXY-2-HALOETHYL) ] -PYRAZINE DERIVATIVES BY ENZYMATIC REDUCTION OF THE CORRESPONDING KETONES F. HOFFMANN-LA ROCHE AG (CH) 2008-10-16 WO disclosed
US-20080248537-A1 BIOCATALYTIC ASYMMETRIC REDUCTION IN PREPARATION OF (S)-N-[5-(1,2-DIHYDROXY-ETHYL)-PYRAZINYL]-2,2-DIMETHYL-PROPIONAMIDE F. HOFFMANN-LA ROCHE AG (CH) 2008-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080248537-A1 BIOCATALYTIC ASYMMETRIC REDUCTION IN PREPARATION OF (S)-N-[5-(1,2-DIHYDROXY-ETHYL)-PYRAZINYL]-2,2-DIMETHYL-PROPIONAMIDE GCK, HK2, GCKR ALDH1A1 180/4885FAAH 1878/4885KMT2A 547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.